Stocks Health care IDXG
OTC · Health careInterpace Biosciences, Inc. (IDXG)
Interpace Biosciences, Inc. brought in $36.1M of revenue over the twelve months to June 30, 2026, down 20.5% from a year earlier. Net income was $24.4M, a net margin of 67.6%. Operating cash flow minus capital spending left $5.5M of free cash flow in fiscal 2025. At June 30, 2026 it held $2.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Watch IDXG in 60 secondsWhat Interpace Biosciences, Inc. does
Interpace Biosciences, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker IDXG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $38.7M | $24.6M | $0.89 | $5.5M |
| 2024 | $46.9M | $6.7M | $0.40 | $3.8M |
| 2023 | $40M | $2M | $0.45 | $3.3M |
| 2022 | $31.8M | -$22M | -$12.95 | -$8M |
| 2021 | $33.1M | -$14.9M | -$9.03 | -$9.1M |
| 2020 | $32.4M | -$26.5M | -$18.30 | -$15.6M |
Full financial statements: income, balance sheet and cash flow
Where IDXG ranks in Health care
Latest SEC filings
What Interpace Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026IPO registration S-1
- September 17, 2026
- August 27, 2026
- August 26, 2026
- August 21, 2026
- August 12, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 1.1% to $9.1M versus the same quarter last year; diluted EPS $0.01 versus -$0.14.
- July 7, 2026Additional proxy material DEFA14A
- July 7, 2026Proxy statement DEF 14A
- June 25, 2026Form PREM14A filing PREM14A
What is IDXG worth? A DCF from its reported cash flow
Insider trades
What the people running Interpace Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 20, 2026 | McCarthy ChristopherCFO & COO | Exercised options | 277,009 | - |
| August 20, 2026 | Burnell Thomas W.CEO, President & Chairman, Director | Exercised options | 1,966,763 | - |
| August 20, 2026 | Burnell Thomas W.CEO, President & Chairman, Director | Shares withheld for tax | 581,718 | $936.6K |
| January 20, 2026 | 1315 Capital II, L.P.10% owner | Exercised options | 9,405,941 | $19M |
| January 20, 2026 | Ampersand 2018 Limited Partnership10% owner | Exercised options | 13,861,386 | $28M |
Who owns IDXG
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
4 insiders reported holding 25,047,054 shares in total, about $160.6M at the last price.
| Holder | Shares |
|---|---|
| Ampersand 2018 Limited Partnership10% owner | 13,861,386 |
| 1315 Capital II, L.P.10% owner | 9,405,941 |
| Burnell Thomas W.CEO, President & Chairman, Director | 1,455,927 |
| McCarthy ChristopherCFO & COO | 323,800 |
Questions about IDXG
What does Interpace Biosciences, Inc. do?
Interpace Biosciences, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker IDXG.
Is Interpace Biosciences, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $24.4M on revenue of $36.1M, a net margin of 67.6%.
How much revenue does Interpace Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Interpace Biosciences, Inc. reported revenue of $36.1M. That is 20.5% less than a year earlier.
When did Interpace Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from September 25, 2026.
Similar companies
Compare IDXG with
Follow IDXG
Get an email when Interpace Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow IDXG: get an email when it filesWhere the numbers come from
Financial figures are the values Interpace Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.